Alivus Life

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE03Q201024
  • NSEID: ALIVUS
  • BSEID: 543322
INR
1,434.15
-15.7 (-1.08%)
BSENSE

Nov 20

BSE+NSE Vol: 1.51 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1003513,
    "name": "Alivus Life",
    "stock_name": "Alivus Life",
    "full_name": "Alivus Life Sciences Ltd",
    "name_url": "stocks-analysis/alivus-life",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,434.15",
    "chg": -15.7,
    "chgp": "-1.08%",
    "dir": -1,
    "prev_price": "1,449.85",
    "mcapval": "17,801.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543322,
    "symbol": "ALIVUS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE03Q201024",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.51 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/alivus-life-1003513-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Alivus Life Sciences Ltd is Rated Buy",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-buy-4260648",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AlivusLifeScien_mojoScore_4260648.png",
        "date": "2026-11-13 10:10:45",
        "description": "Alivus Life Sciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 October 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 13 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Alivus Life Sciences Gains 5.17%: 4 Key Factors Driving the Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-gains-517-4-key-factors-driving-the-week-4255089",
        "imagepath": "",
        "date": "2026-11-07 12:02:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> New 52-week high at Rs.1,504</p>\n                    <p><strong>4 Nov:</strong> Stock hits Rs.1,504.3 amid market rally</p>\n                    <p><strong>5 Nov:</strong> New 52-week high at Rs.1,532.95 despite slight intraday dip</p>\n                    <p><strong>6 Nov:</strong> Week closes at Rs.1,480.55 (-1.12% on day)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,407.80</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,480.55</div><div class=\"stat-change po..."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1532.95",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-ltd-hits-new-52-week-high-at-rs153295-4252260",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AlivusLifeScien_priceRelatedfactors_4252260.png",
        "date": "2026-11-05 10:20:29",
        "description": "Surging to a new 52-week and all-time high of Rs 1,532.95 on 5 Nov 2026, Alivus Life Sciences Ltd has demonstrated remarkable price momentum, outpacing the Sensex’s subdued performance over the past year. The stock’s 64.52% gain contrasts sharply with the Sensex’s 5.53% decline, underscoring a strong technical rally amid a broadly positive market backdrop."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Alivus Life Sciences Ltd to 52-Week High of Rs 1504.3",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-ltd-hits-new-52-week-high-at-rs15043-4250399",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AlivusLifeScien_priceRelatedfactors_4250399.png",
        "date": "2026-11-04 10:00:14",
        "description": "Surging to a new all-time peak of Rs 1504.3 on 4 Nov 2026, Alivus Life Sciences Ltd has demonstrated remarkable price momentum, outperforming the broader market with a 62.64% gain over the past year against the Sensex’s decline of 7.41%. This milestone caps a sustained rally that has seen the stock climb steadily from its 52-week low of Rs 830, reflecting a strong alignment of technical indicators across multiple timeframes."
      },
      {
        "title": "Alivus Life Sciences Ltd is Rated Buy by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-buy-by-marketsmojo-4247307",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AlivusLifeScien_mojoScore_4247307.png",
        "date": "2026-11-02 10:10:25",
        "description": "Alivus Life Sciences Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 October 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Alivus Life Sciences Gains 12.87%: 3 Key Factors Driving the Surge",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-gains-1287-3-key-factors-driving-the-surge-4245641",
        "imagepath": "",
        "date": "2026-10-31 12:02:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>26 Oct:</strong> Stock opens week at Rs.1,262.20, up 1.19%</p>\n                    <p><strong>27 Oct:</strong> Strong 6.44% jump to Rs.1,343.45 amid valuation upgrade talk</p>\n                    <p><strong>28 Oct:</strong> Valuation shifts to expensive; stock closes at Rs.1,400.50 (+4.25%)</p>\n                    <p><strong>29 Oct:</strong> Slight dip of 0.20% to Rs.1,397.75 despite Sensex rally</p>\n                    <p><strong>30 Oct:</strong> New 52-week high at Rs.1,497; closes at Rs.1,407.80 (+0.72%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs..."
      },
      {
        "title": "Alivus Life Sciences Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-ltd-reports-strong-quarterly-upswing-amid-positive-financial-trend-4244828",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AlivusLifeScien_fintrenddot_4244828.png",
        "date": "2026-10-30 11:00:27",
        "description": "Alivus Life Sciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended September 2026, signalling a positive shift in its growth trajectory. The company’s latest results reveal record highs across key profitability metrics, reflecting robust operational efficiency and a favourable market environment within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Alivus Life Sciences Ltd Valuation Shifts Amid Strong Market Performance",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/alivus-life-sciences-ltd-valuation-shifts-amid-strong-market-performance-4241382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AlivusLifeScien_valuationdot_4241382.png",
        "date": "2026-10-28 08:01:04",
        "description": "Alivus Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a previously fair valuation to an expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, invites a closer examination of the stock’s price attractiveness relative to its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Alivus Life Sciences Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/alivus-life-sciences-ltd-is-rated-hold-4233355",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AlivusLifeScien_mojoScore_4233355.png",
        "date": "2026-10-22 10:10:49",
        "description": "Alivus Life Sciences Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 4 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 October 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance."
      }
    ],
    "total": 71,
    "sid": "1003513",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/alivus-life-sciences-1003513"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "19-Nov-2026",
      "details": "Please find enclosed herewith intimation for Analyst/Investor meeting.",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 - Updates",
      "datetime": "11-Nov-2026",
      "details": "Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR) 2015.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Updates on Acquisition",
      "datetime": "11-Nov-2026",
      "details": "Enclosed please find herewith update on acquisition.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Alivus Life Sciences Ltd has declared <strong>250%</strong> dividend, ex-date: 01 Sep 26",
          "dt": "2026-09-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

19-Nov-2026 | Source : BSE

Please find enclosed herewith intimation for Analyst/Investor meeting.

Announcement Under Regulation 30 - Updates

11-Nov-2026 | Source : BSE

Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR) 2015.

Announcement under Regulation 30 (LODR)-Updates on Acquisition

11-Nov-2026 | Source : BSE

Enclosed please find herewith update on acquisition.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Alivus Life Sciences Ltd has declared 250% dividend, ex-date: 01 Sep 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available